# Cancer biology: templates

> Publication-quality cancer-biology figures and graphical abstracts, built from live generators and 3D models: the hallmarks of cancer, the tumour microenvironment, checkpoint blockade, CAR-T therapy, the metastatic cascade, antibody–drug conjugates, nanomedicine and the EPR effect, liquid biopsy, organoid and CRISPR screens, immunotherapy resistance and the colorectal adenoma–carcinoma sequence. Every figure cites its papers.

URL: https://www.labcanvas.com/templates/cancer-biology

12 templates. All templates: https://www.labcanvas.com/templates

- [Hallmarks of cancer (2022)](https://www.labcanvas.com/templates/cancer-biology/hallmarks-cancer-2022) ([Markdown](https://www.labcanvas.com/templates/cancer-biology/hallmarks-cancer-2022.md)): A publication-ready overview of the hallmarks of cancer. The fourteen-spoke Hanahan 2022 wheel — eight hallmark capabilities, four enabling characteristics and two new dimensions — sits beside the three editions (the original six of 2000, the ten of 2011, the fourteen of 2022) and the drug classes that target each hallmark. Every capability and drug class is named as in the papers.
- [The tumour microenvironment](https://www.labcanvas.com/templates/cancer-biology/tumour-microenvironment) ([Markdown](https://www.labcanvas.com/templates/cancer-biology/tumour-microenvironment.md)): A figure of the tumour microenvironment: a 3D cross-section with every cell type recognisable — cancer cells, cancer-associated fibroblasts, M1 and M2 macrophages, CD8⁺ T cells, Tregs, NK and dendritic cells, MDSCs, endothelium, pericytes and adipocytes in their collagen matrix — beside a fully labelled 2D scene and the three immune phenotypes (inflamed, excluded, desert). Cell sizes and the oxygen diffusion limit are to scale.
- [Immune checkpoint blockade](https://www.labcanvas.com/templates/cancer-biology/immune-checkpoint-blockade) ([Markdown](https://www.labcanvas.com/templates/cancer-biology/immune-checkpoint-blockade.md)): A figure of checkpoint blockade in cancer immunotherapy. The 3D immune-synapse model shows PD-1/PD-L1 engaged — recruiting SHP-2 to switch the T cell off — then an anti-PD-1 antibody and an anti-CTLA-4 antibody releasing the brake. It sets out where each checkpoint acts (CTLA-4 at priming in the lymph node, PD-1/PD-L1 at the effector phase in the tumour) and names the approved antibodies.
- [CAR-T cell therapy](https://www.labcanvas.com/templates/cancer-biology/car-t-cell-therapy) ([Markdown](https://www.labcanvas.com/templates/cancer-biology/car-t-cell-therapy.md)): A figure of CAR-T cell therapy. The 3D model shows the chimeric antigen receptor — scFv through hinge, transmembrane domain and costimulation to CD3ζ — and a CAR-T cell killing a CD19⁺ leukaemic blast. Beside them, the five CAR generations module by module, and the manufacturing route from leukapheresis to infusion. Architecture as in June et al. 2018.
- [The metastatic cascade](https://www.labcanvas.com/templates/cancer-biology/metastatic-cascade) ([Markdown](https://www.labcanvas.com/templates/cancer-biology/metastatic-cascade.md)): A figure of the invasion–metastasis cascade. A 3D cut-open block of tissue carries all seven steps — EMT, invasion through the basement membrane, intravasation, a platelet-cloaked CTC cluster, extravasation, a dormant micrometastasis and a vascularised macrometastasis — beside the seed-and-soil organotropism of breast cancer to bone, lung, liver and brain, with the pre-metastatic niche. Steps as in Valastyan & Weinberg 2011.
- [Antibody–drug conjugate mechanism](https://www.labcanvas.com/templates/cancer-biology/antibody-drug-conjugate-mechanism) ([Markdown](https://www.labcanvas.com/templates/cancer-biology/antibody-drug-conjugate-mechanism.md)): A figure of how an antibody–drug conjugate works. The 3D model shows the ADC — a monoclonal antibody carrying cytotoxic payloads on cleavable linkers at a drug-to-antibody ratio of 4 — and the 2D mechanism takes it through binding the tumour antigen, internalisation, lysosomal linker cleavage, payload release and the bystander effect. The three components and named ADCs are set out alongside.
- [Nanomedicine and the EPR effect](https://www.labcanvas.com/templates/cancer-biology/nanomedicine-epr-effect) ([Markdown](https://www.labcanvas.com/templates/cancer-biology/nanomedicine-epr-effect.md)): A figure of how nanomedicines reach a tumour. A 3D cutaway contrasts a normal vessel — tight junctions, draining lymphatics — with a leaky tumour vessel whose endothelial gaps let nanoparticles out, and whose collapsed lymphatics keep them in: the enhanced permeability and retention (EPR) effect. A PEGylated carrier and a 2D tumour scene show the reality — limited penetration and uptake by macrophages — and the delivery efficiency actually measured.
- [Liquid biopsy](https://www.labcanvas.com/templates/cancer-biology/liquid-biopsy) ([Markdown](https://www.labcanvas.com/templates/cancer-biology/liquid-biopsy.md)): A figure of what a blood sample reveals about a tumour. Three 3D scenes show the analytes of a liquid biopsy — circulating tumour cells (single and in platelet-cloaked clusters), circulating tumour DNA as nucleosome-sized fragments, and exosomes — and how CTCs are captured on an anti-EpCAM microchip. The three analytes and their real sizes are set out alongside.
- [Patient-derived organoid drug screen](https://www.labcanvas.com/templates/cancer-biology/patient-derived-organoid-drug-screen) ([Markdown](https://www.labcanvas.com/templates/cancer-biology/patient-derived-organoid-drug-screen.md)): A figure of a patient-derived organoid drug screen. Tumour organoids grown from a patient in a basement-membrane dome keep the tumour’s histology and mutations; dispensed into plates and exposed to a dose series of drugs, they shrink and die as each line passes its IC50. The workflow runs from resection to viability readout, and the organoids can predict how the patient responds.
- [CRISPR screen for cancer dependencies](https://www.labcanvas.com/templates/cancer-biology/crispr-screen-cancer-dependencies) ([Markdown](https://www.labcanvas.com/templates/cancer-biology/crispr-screen-cancer-dependencies.md)): A figure of a pooled CRISPR–Cas9 knockout screen for cancer dependencies. A genome-wide sgRNA library is delivered by lentivirus at low multiplicity so each cell carries one guide and loses one gene; the cells grow, and the abundance of each guide is compared early versus late by sequencing. Guides that drop out mark the genes the cancer needs — its dependencies and candidate drug targets.
- [Immunotherapy resistance](https://www.labcanvas.com/templates/cancer-biology/immunotherapy-resistance) ([Markdown](https://www.labcanvas.com/templates/cancer-biology/immunotherapy-resistance.md)): A figure of why cancer immunotherapy fails. Three 3D scenes contrast a hot (inflamed) tumour, where T cells reach the cancer cells, with a cold (immune-desert) tumour that keeps them out, and an exhausted T cell co-expressing PD-1, LAG-3 and TIM-3. Over the immunoediting escape frame, it sets out the mechanisms of primary and acquired resistance — immune exclusion, antigen and MHC loss, interferon-pathway mutations and T-cell exhaustion.
- [Colorectal adenoma–carcinoma sequence](https://www.labcanvas.com/templates/cancer-biology/colorectal-adenoma-carcinoma-sequence) ([Markdown](https://www.labcanvas.com/templates/cancer-biology/colorectal-adenoma-carcinoma-sequence.md)): A figure of the colorectal adenoma–carcinoma sequence. Normal epithelium becomes an early adenoma when APC is lost and Wnt switches on, grows through intermediate and late adenomas as KRAS and then SMAD4/18q are hit, and turns into carcinoma when TP53 is lost — the classic Fearon–Vogelstein model. Each driver gene is explained, with the principle that the accumulation of mutations matters more than their order.

## Drawing cancer biology figures

These templates cover the ideas a cancer-biology figure most often has to carry: the hallmarks of cancer, the tumour microenvironment, the immune mechanisms behind checkpoint blockade and CAR-T therapy, the metastatic cascade, the main therapeutic modalities (antibody–drug conjugates, nanomedicine), and the models and liquid biopsies used to study and monitor tumours. Each is built for review figures, graphical abstracts, teaching slides and talks, where a mechanism has to be shown accurately and legibly rather than as a generic cartoon.

Every panel is a live generator or a 3D Studio model drawn from the papers the template cites, and every number on the figure is quoted from those papers. Cells are drawn at their real relative sizes; molecules, vessels and fragments are schematic where the caption says so. The science and the references sit on each template’s page, with checked DOIs.

### Get the numbers and the names right

- **Cell sizes.** A CD8⁺ T cell is about 7–10 µm, a macrophage about 15–20 µm and a red cell about 7.5 µm. Keeping these ratios makes a microenvironment panel read correctly at a glance.
- **Oxygen and necrosis.** Oxygen reaches only about 100–200 µm from a capillary before tissue turns hypoxic and then necrotic (Thomlinson & Gray, Br. J. Cancer 1955); draw a spheroid’s necrotic core at that distance, not at random.
- **Current nomenclature.** Use the 2022 hallmarks (Hanahan, Cancer Discov. 2022), the CAR generations as defined in June et al., Science 2018, and the real drug names (nivolumab and pembrolizumab for PD-1, atezolizumab for PD-L1, ipilimumab for CTLA-4, relatlimab for LAG-3).
- **Molecular dimensions.** An IgG is about 150 kDa with twelve Ig domains and N-glycans at Asn297; the TCR–pMHC close contact spans about 13–15 nm, which excludes the large phosphatase CD45; plasma cell-free DNA peaks at about 166 bp. These are what make a molecular panel look expert.

### Be honest about what therapies deliver

It is easy to overstate a mechanism in a graphical abstract. Two cases recur. The enhanced permeability and retention (EPR) effect is real but inefficient: a meta-analysis by Wilhelm and colleagues (Nat. Rev. Mater. 2016) found a median of about 0.7% of an injected nanoparticle dose reaches solid tumours in published animal studies, so a figure that floods a tumour with particles misleads. And checkpoint blockade works only where T cells can reach the tumour, recognise it and still function; the nanomedicine and immunotherapy-resistance templates draw these limits rather than hiding them.

Where a figure shows a trend rather than measured data — a dropout curve in a CRISPR screen, a dose response in an organoid screen — say so in the caption. The templates mark these panels as illustrations, not data.

### Keep scales readable

- **Use insets and keys.** A tumour spans centimetres, its cells tens of micrometres and an antibody a few nanometres. Zoom between scales with boxes and lines, and give every cell type a colour in a key that stays the same across panels.
- **Separate schematic from data.** Keep cartoon panels free of numbers that look like measurements; put real measurements in a plot with units. The Graphs app has the oncology plots (waterfall, spider, swimmer, tumour-growth curves) for the quantitative panels.
- **One colour per player.** Give the cancer cell, the T cell, the drug and the payload one colour each throughout the figure, so a reader can follow them from panel to panel.

## Questions

**Which edition of the hallmarks of cancer should I use?** The current one is Hanahan 2022 (Cancer Discov.), with eight hallmark capabilities, four enabling characteristics and the new dimensions of phenotypic plasticity, epigenetic reprogramming, polymorphic microbiomes and senescent cells. The hallmarks template also draws the 2000 and 2011 editions for historical context.

**Are the structures and scenes in these templates real?** The 3D models and generators are built from the cited papers at real dimensions and relative cell sizes, but the specific arrangements are schematic examples to replace with your own. Numbers in the captions are quoted from the papers; panels that show a trend rather than data say so.

**Can I use these figures in a publication?** Yes. Open a template in the LabCanvas editor, change anything, and export PNG, TIFF or PDF at journal sizes and DPI. Cite the primary papers listed on the template’s page, and keep the “schematic” and “not to scale” notes where the biology is simplified.
